News & Events

Press Releases

September 26, 2023

Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing

September 20, 2023

Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform

September 13, 2023

Kyverna Therapeutics Announces Achievement of 28-Day Post-Infusion Milestone for First U.S. Patient Dosed in Phase 1 Clinical Trial of CD19 CAR T-Cell Therapy for Lupus Nephritis

September 8, 2023

Kyverna Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 7, 2023

Verily and Kyverna Therapeutics Announce Collaboration to Advance Cell Therapy for Autoimmune Diseases

August 3, 2023

Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors

July 6, 2023

Kyverna Therapeutics Announces Regulatory Approval of Phase 1/2 Clinical Trial for KYV-101 in Germany

June 29, 2023

Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S.

June 1, 2023

Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis

May 24, 2023

Kyverna Therapeutics to Present New Data of KYV-101 in Lupus at European Congress of Rheumatology

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com